Clinical Trials
123 trialsNCT05064059 2026-05-26
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT07284849 2026-05-26
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Phase 3 Recruiting
NCT05239741 2026-05-22
MK-3475-C66
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT07595276 2026-05-19
Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase 3 Not yet recruiting
NCT05652894 2026-05-14
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3 Active not recruiting
NCT03426371 2026-05-12
Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3 Terminated
NCT04835142 2026-05-08
Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 3 Completed
NCT06662786 2026-05-08
OrigAMI-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT06750094 2026-05-08
OrigAMI-3
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT07549412 2026-05-08
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
EMD Serono
Phase 3 Recruiting
NCT07228832 2026-05-05
HARMONi-GI3
Summit Therapeutics
Phase 3 Recruiting
NCT04793958 2026-04-27
KRYSTAL-10
Mirati Therapeutics Inc.
Phase 3 Active not recruiting
NCT05198934 2026-04-27
CodeBreak300
Amgen
Phase 3 Completed
NCT06252649 2026-04-24
CodeBreaK 301
Amgen
Phase 3 Recruiting
NCT07222800 2026-04-21
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Phase 3 Recruiting
NCT07525206 2026-04-13
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
AbbVie
Phase 3 Not yet recruiting
NCT05253651 2026-04-07
MOUNTAINEER-03
Seagen Inc.
Phase 3 Recruiting
NCT06497985 2026-03-19
A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR Colorectal Cancer Patients
Chipscreen Biosciences, Ltd.
Phase 3 Recruiting
NCT03362177 2026-02-11
RECITE
Amgen
Phase 3 Completed
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04854668 2026-01-30
A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3 Active not recruiting
NCT07361003 2026-01-22
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT03869892 2025-12-22
SOLSTICE
Servier
Phase 3 Active not recruiting
NCT05600309 2025-11-26
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05425940 2025-10-23
STELLAR-303
Exelixis
Phase 3 Active not recruiting
NCT04008030 2025-10-03
CheckMate 8HW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT06614192 2025-08-26
A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
AbbVie
Phase 3 Recruiting
NCT07134205 2025-08-21
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
Phase 3 Not yet recruiting
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT05328908 2025-08-13
RELATIVITY-123
Bristol-Myers Squibb
Phase 3 Terminated
NCT07025239 2025-06-17
QL1706 Injection Plus Bevacizumab and XELOX vs Placebo Plus Bevacizumab and XELOX as First-Line Treatment of Unresectable Metastatic Colorectal Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT03206151 2025-05-23
CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer
Taizhou Mabtech Pharmaceutical Co.,Ltd
Phase 3 Completed
NCT04322539 2025-04-04
FRESCO-2
Hutchmed
Phase 3 Completed
NCT03511963 2024-12-31
A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC
Shanghai Henlius Biotech
Phase 3 Completed
NCT04607668 2024-11-26
PRESERVE1
G1 Therapeutics, Inc.
Phase 3 Terminated
NCT04456699 2024-10-29
LYNK-003
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02563002 2024-10-03
KEYNOTE-177
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04737187 2024-09-24
SUNLIGHT
Taiho Oncology, Inc.
Phase 3 Completed
NCT01607957 2024-09-19
RECOURSE
Taiho Oncology, Inc.
Phase 3 Completed
NCT05223673 2024-08-20
COLSTAR
Servier
Phase 3 Terminated
NCT03306394 2024-07-25
PRECONNECT
Servier
Phase 3 Completed
NCT03659448 2024-04-24
Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
Surgimab
Phase 3 Recruiting
NCT02928224 2023-12-21
BEACON CRC
Pfizer
Phase 3 Completed
NCT02753127 2023-11-15
CanStem303C
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT02394795 2023-11-01
PARADIGM
Takeda
Phase 3 Completed
NCT04233151 2023-05-26
QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety
Qilu Pharmaceutical Co., Ltd.
Phase 3 Unknown
NCT03391934 2023-04-05
Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer
Cinnagen
Phase 3 Unknown
NCT00642577 2022-12-22
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
Hoffmann-La Roche
Phase 3 Completed
NCT02870582 2022-11-29
Donafenib for Previously Treated Metastatic Colorectal Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3 Completed
NCT00113763 2022-11-07
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
Amgen
Phase 3 Completed